In-house R&D and innovation has marked the rise of Gharda Chemicals Ltd. (GCL) from a small unit in 1964 to one of the most successful and reputed companies in the field of Agro-chemicals worldwide. A strong and vibrant R&D program and expertise in Process Development coupled with a team of outstanding scientists headed by Dr.K.H.Gharda, has enabled the company to capitalise on superior technology generated in-house. This has led to the production of vital import substitute products and cost-effective Agro-chemicals on a large scale now affordable to even marginal farmers at the national filme porno level and a strong competitive international presence, saving foreign-exchange outgo, on one hand and earning significant foreign exchange.
Welcome to the Bayer CropScience home page! Here, you can get all the information you need to help you grow your crops. You can learn about the effectiveness of Bayer CropScience products. Access newsletters and useful online sites. Or communicate with our Customer Interaction Center for crop and product questions or comments. You can do it all at BayerCropScienceUS.com!
IGNITE Herbicide Now Available for LibertyLink Cotton
Cotton growers now have a new alternative in weed control. IGNITE herbicide has received federal registration for use on cotton. This non-selective, contact herbicide that controls more than 100 weeds is now available for use on LibertyLink cotton varieties.
Leverkusen – Professor Dr. Friedrich Berschauer (53), currently a member of the Board of Management of Bayer HealthCare AG and Head of its Animal Health Division, has been named Chairman of the Board of Management of Bayer CropScience AG effective April 1, 2004. He succeeds Dr. Jochen Wulff (64), who will retire after 35 years of porno carioca’ valuable service to Bayer. The new Head of Animal Health will be Dr. Gunnar Riemann (45), presently in charge of the Biological Products Division. Riemann will also join the Board of Management of Bayer HealthCare AG.
Friedrich Berschauer was born in Boms, near Ravensburg in southern Germany, on June 29, 1950. He studied agricultural science at Stuttgart-Hohenheim University, subsequently working as a scientific assistant at the university’s Institute for Animal Nutrition. After obtaining his doctorate in agricultural science in 1977, he joined Bayer AG in 1980 as head of the animal nutrition department at the Pharmaceuticals Research Center in Wuppertal. He held various other positions with Bayer before becoming head of development in the company’s Crop Protection Business Group in 1993.
In 1998 he transferred to the United States, serving as President of the Animal Health Division of Bayer Corporation. In July 2000 he was appointed General Manager of the Animal Health Business Group at Bayer AG. After the reorganization, Berschauer initially was appointed a member of the Bayer HealthCare Executive Committee with responsibility for the Animal Health Division and the Asia-Pacific region. Effective October 1, 2003 he became a member of the Board of Management of Bayer HealthCare AG and the company’s labor director.
Since 1987 Berschauer has been working as an adjunct professor at the University of Stuttgart-Hohenheim. He is married with three children.
. Dr. Gunnar Riemann
Gunnar Riemann was born in Hamelin, Germany, on October 26, 1958. He majored in pharmacy and obtained his doctorate at the Technical University of Brunswick, Germany, starting his career with Bayer in 1986 at the Institute for Pharmaceutical Technology in Leverkusen. In 1987 he was appointed manager of a pharmaceuticals production facility. In 1991 Riemann transferred to the United States to work for the Bayer subsidiary then known as Miles Inc. in Elkhart, Indiana, as head of product development for OTC products.
Riemann returned to Leverkusen in 1994 to head up the Household Products Business Unit in the Consumer Care Business Group. In 1996 he was appointed this business group’s regional manager for Asia and South America, and from 1999 until September 2001 he was responsible for Consumer Care’s Europe region. He was then placed in charge of Bayer’s Biological Products Business Group, headquartered in the United States. Riemann also served as an Executive Vice President and Member of the Executive Committee of Bayer Corporation, and on July 1, 2002 joined the Executive Committee of Bayer HealthCare.
Dr. Riemann is married with three children.
. Dr. Jochen C. Wulff
Dr. Jochen C. Wulff has been Chairman of the Board of Management of Bayer CropScience since July 1, 2002. After studying and obtaining a doctorate in organic chemistry, he joined the research department of what was then Bayer’s U.S. subsidiary Mobay Corporation in 1968. After holding various positions in the Polyurethanes Business Group, both at Mobay and at Bayer’s headquarters in Leverkusen, he was appointed manager of a dyestuffs production unit in Leverkusen in 1984. He returned to Mobay in 1986 as Executive Vice President Production and Technology, becoming Mobay’s President and Chief Executive Officer in 1990. Dr. Wulff left the United States following the reorganization of Bayer’s U.S. operations. In April 1993 he was appointed General Manager of Bayer AG’s Crop Protection Business Group, which was later successfully realigned and combined with the acquired company Aventis CropScience to form today’s Bayer CropScience AG.
This subgroup of Bayer AG has 20,000 employees, annual sales of about EUR 5.7 billion and is represented in 122 countries. One of the world’s leading innovative crop science companies, it is active in the areas of crop protection, non-agricultural pest control, seeds and plant biotechnology.
Bayer HealthCare AG, also a subgroup of Bayer AG, had sales of some EUR 9.4 billion in 2002. It is among the world’s leading innovative companies in the health care and medical products industry, with a global workforce of more than 34,000. Bayer HealthCare combines the global activities of the Animal Health, Biological Products, Consumer Care, Diagnostics and Pharmaceuticals divisions.
This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.